Brazilian company partners with German company and announces strategic advancement in the national market

CannTen, an international company in the medicinal cannabis sector with operations in Brazil, announced the signing of a commercial agreement with an international partner for the early purchase of a significant volume of products. The operation is considered by the company as one of the main commercial advancements since the beginning of its activities in the country.

Agreement involves product registered with Anvisa

The agreement provides commercial support for one of CannTen's products registered with the National Health Surveillance Agency (Anvisa), with direct distribution to pharmacies throughout the national territory. The partnership involves TWA Brands from Germany, which is entering the Brazilian market through this operation.

According to the company, the initiative aims to expand its participation in the Brazilian medicinal cannabis market and serves as a starting point for TWA Brands' activities in the country. CannTen is part of Shizim, an integrated center for sciences, research, innovation, and health technology based in Israel, with operations in different areas of the biomedical ecosystem internationally.

Expansion marks TWA Brands' entry into Brazil

Commenting on the strategic impact of the agreement on the company's operations in Brazil, CannTen's CEO, Ori Alperovitz, emphasized the relevance of the partnership for the company's consolidation in the country. He stated,
"We are very pleased to sign the most important commercial agreement in the history of our company in Brazil. This partnership reinforces our deep commitment to the Brazilian market—not only by providing the highest quality products but also by sharing over a decade of experience working with doctors and patients worldwide, and introducing advanced technologies in compliance with local regulations."

According to the company's assessment, the agreement can also contribute to expanding access to cannabis-based treatments through the pharmaceutical channel, respecting the current regulatory requirements in the country.

Company highlights impact on the sector and patients

From the perspective of the impact on the sector and patients, CannTen's director, Dr. José Almeida, emphasized the importance of the initiative for the expansion of cannabinoid medicine in Brazil. He stated,
"This milestone represents an important step, as it represents the possibility of expanding access to cannabinoid medicine through medical prescriptions to patients throughout Brazil. Through solid local partnerships, positioning CannTen as a reference in the country's medicinal cannabis sector."

Strategy remains guided by technical and regulatory criteria

CannTen stated that its strategy in Brazil remains guided by technical and regulatory criteria, focusing on evidence-based medicine, interaction with the medical community, and expanding a product portfolio. In a statement, the company affirmed that "it reaffirms its commitment to evidence-based medicine, the medical community, and patients, investing in an innovative, quality, and comprehensive portfolio, allowing the prescriber to choose the ideal product according to the pathology and the needs of each patient," adding that "all our products undergo rigorous national and international quality controls and are recognized by Anvisa."